


Debutyldronedarone hydrochloride

Cat. No.:	HY-12753A
CAS No.:	197431-02-0
Molecular Formula:	C ₂₇ H ₃₇ ClN ₂ O ₅ S
Molecular Weight:	537.11
Target:	Thyroid Hormone Receptor
Pathway:	Others
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (186.18 mM)					
	* "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	1.8618 mL	9.3091 mL	18.6182 mL
			5 mM	0.3724 mL	1.8618 mL	3.7236 mL
10 mM			0.1862 mL	0.9309 mL	1.8618 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.65 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α ₁ (TRα ₁) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα ₁ and TRβ ₁ by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic ^[1] .
IC ₅₀ & Target	TRα ₁ /TRβ ₁ ^[1]

REFERENCES

[1]. Van Beeren HC, et al. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. *Endocrinology*. 2003 Feb;144(2):552-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA